GlassScriptPhysician profile
Lynn C Baker
NPI 1295970093
$4,271.83
in general payments reported to CMS, 2019-2025
23 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,037 · 2022: $1,027 · 2023: $472 · 2024: $673 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.21 |
| Education | $185.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,092.23 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $574.37 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $448.17 | 2021-2025 | |
| Janssen Biotech, INC. | $436.55 | 2021-2025 | Tremfya |
| Ucb, INC. | $313.54 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $310.16 | 2021-2024 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $177.07 | 2021-2025 | Adbry |
| Genzyme Corporation | $149.17 | 2022-2025 | |
| Pfizer INC. | $105.94 | 2021-2025 | |
| Galderma Laboratories, L.P. | $104.61 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $102.61 | 2021-2025 | Taltz, Ebglyss |
| Almirall LLC | $71.78 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $61.22 | 2024-2025 | Zoryve |
| Epi Health, LLC | $58.65 | 2021-2022 | |
| Tempus Ai, INC | $50.92 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $40.94 | 2021-2023 | Valchlor |
| Organon LLC | $38.56 | 2025 | |
| Incyte Corporation | $36.12 | 2025 | Opzelura |
| Amgen INC. | $25.57 | 2024 | Otezla |
| Biofrontera INC. | $20.57 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Vyne Pharmaceuticals INC. | $19.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.87 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $16.15 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.